ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2026
[Ethanol Extract of
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The ameliorative effects of the ethanol extract of Methods: Ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) was used to analyze the chemical constituents of VTDB. A rat CAG model was established using MNNG induction combined with irregular feeding. Seventy-two healthy male SD rats were randomly divided into six groups: normal control, model, low-dose VTDB (157 mg/[kg·d]), medium-dose VTDB (314 mg/[kg·d]), high-dose VTDB (628 mg/[kg·d]), and positive control (Vatacoenayme) (216 mg/[kg·d]), with 12 rats in each group. HE staining was used to observe pathological changes in the gastric mucosa of each group. ELISA was performed to measure serum levels of pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), and inflammatory factors (TNF-α, IL-6, and IL-10). Levels of malondialdehyde (MDA) and superoxide dismutase (SOD) activity in gastric tissues were determined. Western blot was used to measure the expression levels of heme oxygenase-1 (HO-1)/nuclear factor erythroid-2-related factor 2 (Nrf2) and myeloid differentiation primary response protein 88 (MyD88)/protein kinase B (AKT)/phosphatidylinositide 3-kinase (PI3K) signaling pathway proteins in gastric tissues. Results: By comparing retention times, mass spectral fragmentation patterns, and matching with the ESI (±)-MS/MS database, a total of 89 chemical constituents-primarily fatty acids, phenolic acids, and coumarins-were identified in VTDB. HE staining indicated that VTDB partially improved gastric mucosal damage in CAG rats. ELISA showed that, compared with the model group, the VTDB-treated groups had increased serum levels of PGⅠ, PGⅡ, and PGR (PGⅠ/PGⅡ) ( Conclusion: VTDB reduces gastric damage and inflammation in CAG rats by inhibiting lipid peroxidation and inflammatory processes through its effects on the HO-1/Nrf2 and MyD88/AKT/PI3K signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.